COLARIS®: Hereditary Cancer Testing for Colorectal Cancer, Uterine Cancer

COLARIS® is a genetic test that assesses a person’s risk of developing hereditary colorectal cancer and a woman’s risk of developing hereditary uterine cancer. COLARISPLUS detects disease-causing mutations in the MLH1, MSH2, MSH6, PMS2EPCAM,  and MYH genes that are responsible for the majority of Lynch syndrome and MYH-associated polyposis (MAP) cases.

Lynch syndrome, also known as Hereditary Nonpolyposis Colorectal Cancer (HNPCC), is the most common of the hereditary colon cancer syndromes and is believed to account for 3% to 5% of all colorectal cancers. COLARIS is a test for Lynch syndrome. Knowing the results may help patients and their physicians to take steps to prevent cancer before it has a chance to develop.

MYH-associated polyposis (MAP) is caused by mutations in the mutY homolog (MYH) gene.  Individuals with MAP have mutations in both of their MYH genes (one from each parent, often referred to as "biallelic MYH mutations"). Patients often have no family history of colon cancer or polyps in parents (although siblings may be affected).83 The MYH gene is an important part of the base excision repair (BER) pathway, which allows for repair of DNA mutations caused by oxidative damage to cells.

COLARIS is a simple blood test or oral rinse sample to find out if you have a MLH1, MSH2, MSH6, PMS2, EPCAM or MYH mutation(s). Knowing the results may help you and your doctor act before cancer has a chance to develop.

Benefits of COLARIS Testing

The results of the COLARIS test enable the development of a patient-specific medical management roadmap to significantly reduce the risk of cancer.  COLARIS will help you to:

  • Target increased surveillance and other interventions specifically to individuals with a Lynch Syndrome or MYH-associated polyposis (MAP) mutation(s) - personalizing patient care and increasing clinical efficiency
  • Improve patient compliance with tailored screening recommendations and preventive measures
  • Significantly improve outcomes and reduce medical costs through prevention, earlier diagnosis and treatment of cancer, should it develop
  • Counsel patients and family members on the underlying cause of cancer in their family
  • Avoid unnecessary interventions for family members who do not test positive for the mutation(s) known to be in the family

Medical Management and COLARIS*

Once a diagnosis of Lynch syndrome or MAP is confirmed, the following medical management options may help reduce the risk of cancer or detect cancer at an earlier, more treatable stage.

Colon Cancer (Lynch syndrome and MAP)

  • Increased surveillance for colorectal cancer
  • Surgical management of colorectal cancer

Endometrial and Ovarian Cancer (Lynch syndrome)

  • Surveillance for endometrial and ovarian cancer
  • Surgical management of endometrial and ovarian cancer

Surveillance for Other Lynch Syndrome-Related Cancers (Lynch syndrome)

  • Upper GI endoscopy, urinalysis, physical examinations

*For medical management references, visit www.myriadpro.com/references

NOTE: Any discussion of medical management options is for general informational purposes only and does not constitute a recommendation.  While genetic testing and medical society guidelines provide important and useful information, medical management decisions should be made based on consultation between each patient and his or her healthcare provider.

 

Myriad has developed a Hereditary Cancer Quiz you can use with your patients to help identify who is a candidate for genetic testing using COLARIS.

 

For more physician information or to order a COLARIS test kit, please visit MyriadPro